Three of the world’s largest pharmaceutical firms are dashing to develop a drug that mimics the effects of an exceedingly rare genetic mutation that causes LDL cholesterol levels to be dramatically low, writes Gina Kolata, of the New York Times.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

This Week in Nature

Natural Knockouts

Human Knockouts

This Week in Cell

This Week in PNAS

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.